Ailomics Therapeutics

Ailomics Therapeutics

digitalizes disease biology and

delivers therapeutics of

significant clinical values.

넳 넲

R&D Model

From bedside to bench and to bedside again.

We start from patient samples and data, identify novel targets, develop human disease models, and discover FIC drug candidates, which are then tested back on the patients.

Ailomics Therapeutics is a pharmaceutical R&D startup with a pioneering computational and experimental platform to discover novel targets and develop first-in-class therapeutics for the diseases of significant unmet medical needs.

Ailomics Therapeutics leverages patients-derived omics data and AI-augmented bioinformatics analytics to deeply understand disease biology and identify the targets that drive disease progressions.

Learning from human disease biology, Ailomics Therapeutics develops high-translatability disease models to validate targets and to screen for functional molecules for therapeutic interventions.

The human disease biology insights also enable Ailomics Therapeutics to discover predictive biomarkers and develop companion diagnostics for patient stratification in clinical trials.

넳 넲

Who we are and what we do

Business Models

Internal R&D&C, co-development of therapeutics and companion diagnostics.

We discover, develop and commercialize medicines. Meanwhile, we co-develop therapeutics with pharmaceutical MNCs and companion diagnostics with IVD companies.